CIRI Opens Coronavirus Clinical Trials

The CHI Institute for Research and Innovation (CIRI) has opened two clinical trials for treatment of patients with COVID-19 at CHI Franciscan St. Joseph Medical Center in Tacoma, WA:

Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)
The primary objective of this study is to evaluate the efficacy of two remdesivir (RDV) regimens with respect to the normalization of temperature and oxygen saturation through Day 14 in participants with severe coronavirus disease (COVID-19).

Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment
The primary objective of this study is to evaluate the efficacy of two remdesivir (RDV) regimens compared to standard of care (SOC), with respect to the time to discharge in participants with moderate coronavirus disease (COVID-19).

For more information, please contact Diana Morales or Conchita Purchase.

U.S. COVID-19 cases surpass 18 million

DEC 29, 2020

Dr. Thomas McGinn, executive vice president of Physician Enterprise, discussed the current state of the pandemic, the vaccine rollout, and growth in virtual care.

READ MORE Additional information about U.S. COVID-19 cases surpass 18 million

Don’t Share Your Air

DEC 22, 2020

As the COVID-19 pandemic reaches new heights in communities across the country, CHI provides a simple prescription: Don’t Share Your Air.

READ MORE Additional information about Don’t Share Your Air